Reasons for treatment changes in adults with attention-deficit/hyperactivity disorder: a chart review study.
ADHD
Adult
Chart review
Complications
Discontinuation
Treatment changes
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
03 06 2022
03 06 2022
Historique:
received:
03
12
2021
accepted:
19
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Adults with attention-deficit hyperactivity disorder (ADHD) often cycle through multiple treatments for reasons that are not well documented. This study analyzed the reasons underlying treatment changes among adults treated for ADHD in a real-world setting. Data were collected via an online reporting form completed by eligible physicians between October and November 2020. Data for adult patients in the United States who were diagnosed with ADHD and initiated a treatment regimen within 1 to 5 years of chart abstraction were obtained. Reason for a treatment change was described for a randomly selected regimen episode, which spanned from treatment initiation until the earliest among treatment add-on/switch or discontinuation, death, or date of chart abstraction. The overall rate of ADHD/treatment-related complications were also described. Physician satisfaction with current treatment options for adult ADHD and opinions on areas for improvement were assessed. Data on 320 patients were reported by 152 physicians specializing in psychiatry (40.1%), pediatrics (25.0%), family medicine (21.7%), and internal medicine (13.2%). Patients had a mean age of 29.3 years; most were diagnosed with ADHD as adults (57.5%) and within the previous 5 years (56.5%). Selected treatment regimens included stimulants (79.1%), nonstimulants (14.7%), and combination therapy (5.6%) for an average duration of 1.9 years. Among patients with treatment discontinuation (N = 59), the most common reasons for discontinuation were suboptimal symptom management (55.9%), occurrence of ADHD/treatment-related complications (25.4%), and patient attitude/dislike of medication (25.4%). The main reasons for other key treatment changes were inadequate/suboptimal management of symptoms and cost considerations. Over 40% of patients had ≥ 1 documented ADHD/treatment-related complication, irrespective of whether they led to a treatment change. One in 5 physicians (19.8%) were very dissatisfied, moderately dissatisfied, or neither satisfied nor dissatisfied with current treatment options for ADHD in adults; the top 3 suggested improvements were lower risk of abuse (71.7%), longer effect duration (65.1%), and fewer ADHD/treatment-related complications (61.2%). The top reasons for treatment changes among adults with ADHD are lack of efficacy and ADHD/treatment-related complications, highlighting the importance of developing more effective and safer treatments to alleviate the burden of ADHD.
Sections du résumé
BACKGROUND
Adults with attention-deficit hyperactivity disorder (ADHD) often cycle through multiple treatments for reasons that are not well documented. This study analyzed the reasons underlying treatment changes among adults treated for ADHD in a real-world setting.
METHODS
Data were collected via an online reporting form completed by eligible physicians between October and November 2020. Data for adult patients in the United States who were diagnosed with ADHD and initiated a treatment regimen within 1 to 5 years of chart abstraction were obtained. Reason for a treatment change was described for a randomly selected regimen episode, which spanned from treatment initiation until the earliest among treatment add-on/switch or discontinuation, death, or date of chart abstraction. The overall rate of ADHD/treatment-related complications were also described. Physician satisfaction with current treatment options for adult ADHD and opinions on areas for improvement were assessed.
RESULTS
Data on 320 patients were reported by 152 physicians specializing in psychiatry (40.1%), pediatrics (25.0%), family medicine (21.7%), and internal medicine (13.2%). Patients had a mean age of 29.3 years; most were diagnosed with ADHD as adults (57.5%) and within the previous 5 years (56.5%). Selected treatment regimens included stimulants (79.1%), nonstimulants (14.7%), and combination therapy (5.6%) for an average duration of 1.9 years. Among patients with treatment discontinuation (N = 59), the most common reasons for discontinuation were suboptimal symptom management (55.9%), occurrence of ADHD/treatment-related complications (25.4%), and patient attitude/dislike of medication (25.4%). The main reasons for other key treatment changes were inadequate/suboptimal management of symptoms and cost considerations. Over 40% of patients had ≥ 1 documented ADHD/treatment-related complication, irrespective of whether they led to a treatment change. One in 5 physicians (19.8%) were very dissatisfied, moderately dissatisfied, or neither satisfied nor dissatisfied with current treatment options for ADHD in adults; the top 3 suggested improvements were lower risk of abuse (71.7%), longer effect duration (65.1%), and fewer ADHD/treatment-related complications (61.2%).
CONCLUSIONS
The top reasons for treatment changes among adults with ADHD are lack of efficacy and ADHD/treatment-related complications, highlighting the importance of developing more effective and safer treatments to alleviate the burden of ADHD.
Identifiants
pubmed: 35659281
doi: 10.1186/s12888-022-04016-9
pii: 10.1186/s12888-022-04016-9
pmc: PMC9164343
doi:
Substances chimiques
Central Nervous System Stimulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
377Informations de copyright
© 2022. The Author(s).
Références
Psychopharmacology (Berl). 2020 Sep;237(9):2835-2843
pubmed: 32591937
J Manag Care Pharm. 2004 Mar-Apr;10(2):122-9
pubmed: 15032561
Innov Clin Neurosci. 2012 May;9(5-6):10-21
pubmed: 22808445
Arch Intern Med. 2004 Jun 14;164(11):1221-6
pubmed: 15197048
J Child Psychol Psychiatry. 2014 Aug;55(8):878-85
pubmed: 25158998
Encephale. 2020 Feb;46(1):30-40
pubmed: 31610922
J Atten Disord. 2019 Jul;23(9):1007-1016
pubmed: 28974134
Mol Psychiatry. 2019 Mar;24(3):390-408
pubmed: 29955166
JAMA Netw Open. 2019 May 3;2(5):e194980
pubmed: 31150084
Am J Manag Care. 2018 Jul;24(8 Spec No.):SP329-SP337
pubmed: 30020748
J Manag Care Pharm. 2007 Sep;13(7):570-7
pubmed: 17874863
Expert Rev Neurother. 2016;16(2):131-44
pubmed: 26693882
Neuropsychiatr Dis Treat. 2014 Aug 22;10:1543-69
pubmed: 25187718
Occup Environ Med. 2008 Dec;65(12):835-42
pubmed: 18505771
Sleep Med Clin. 2017 Sep;12(3):383-393
pubmed: 28778236
N Engl J Med. 2012 Nov 22;367(21):2006-14
pubmed: 23171097
Expert Opin Pharmacother. 2019 Aug;20(12):1457-1470
pubmed: 31112441
Pharmacoeconomics. 2021 Apr;39(4):399-420
pubmed: 33554324
PLoS One. 2019 Feb 7;14(2):e0211873
pubmed: 30730956
Eur Psychiatry. 2012 Jul;27(5):343-9
pubmed: 22521805
JAMA Psychiatry. 2014 Mar;71(3):319-25
pubmed: 24477798
BMJ Open. 2018 Mar 2;8(3):e019700
pubmed: 29500213
Postgrad Med. 2019 Sep;131(7):461-472
pubmed: 31340712
Innov Clin Neurosci. 2019 Sep 1;16(9-10):11-16
pubmed: 32082943
Aust N Z J Psychiatry. 2016 Jun;50(6):548-56
pubmed: 26460330
Lancet Psychiatry. 2021 Sep;8(9):774-783
pubmed: 34242595
PLoS One. 2021 Mar 17;16(3):e0247724
pubmed: 33730071
Curr Med Res Opin. 2011;27 Suppl 2:53-62
pubmed: 21973231
Neuropsychiatry (London). 2013 Oct 1;3(5):455-458
pubmed: 24644516
PLoS One. 2018 Sep 26;13(9):e0204516
pubmed: 30256837
Curr Med Res Opin. 2021 Nov;37(11):2007-2014
pubmed: 34427164
J Atten Disord. 2018 Feb;22(3):203-228
pubmed: 27664125
Am J Psychiatry. 2006 Apr;163(4):716-23
pubmed: 16585449